Pfizer pfudges with its withdrawal of Exubera

Share this article:
Pfizer and Nektar have buried the hatchet after the former paid the latter $135 million following its abrupt decision to discontinue marketing of Exubera, on which the two firms partnered. But Pfizer's handling of the matter could do lasting damage to the company's reputation—particularly among its prospective partners.

Pfizer CEO Jeff Kindler notified the public of his decision to cease marketing the inhalable diabetes drug due to poor earnings during a third quarter earnings call. Trouble is, Pfizer didn't bother to clue in Nektar Therapeutics on the decision in advance.

“We first learned…of Pfizer's decision to walk away from Exubera from their press release,” said Howard Robin, Nektar president and CEO, in a statement.

Pfizer cited SEC rules in explaining why it didn't notify the company. Some analysts still criticized Pfizer's conduct.

“We were taken aback by the manner in which [Pfizer] management handled the situation,” Morgan Stanley analyst Jami Rubin wrote in a research note.

WR Hambrecht's Andrew Forman called Nektar's pact with Pfizer “a bad marriage with all the baggage of disappointing expectations.”

Pfizer acknowledged that it “underestimated” all the barriers to getting patients started on insulin in an inhalable form, not just the size of the device.

Now Nektar is left with a 100% stake in a drug Pfizer couldn't sell, Forman wrote. Pfizer, some analysts noted, is set to lose $8 billion on Lipitor as early as 2010 and needs to replace that largely by striking in-licensing deals.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?